- 2004 Indian Ocean tsunami: what to know 20 years on
- Russian state owner says cargo ship blast was 'terrorist attack'
- Sweeping Vietnam internet law comes into force
- Thousands attend Christmas charity dinner in Buenos Aires
- Demand for Japanese content booms post 'Shogun'
- Mystery drones won't interfere with Santa's work: US tracker
- Global stocks mostly higher in thin pre-Christmas trade
- NASA probe makes closest ever pass by the Sun
- Global stocks mostly rise in thin pre-Christmas trade
- Global stocks mostly rise after US tech rally
- Investors swoop in to save German flying taxi startup
- Saving the mysterious African manatee at Cameroon hotspot
- The tsunami detection buoys safeguarding lives in Thailand
- Asian stocks mostly up after US tech rally
- US panel could not reach consensus on US-Japan steel deal: Nippon
- The real-life violence that inspired South Korea's 'Squid Game'
- El Salvador Congress votes to end ban on metal mining
- Five things to know about Panama Canal, in Trump's sights
- Mixed day for global stocks as market hopes for 'Santa Claus rally'
- Trump's TikTok love raises stakes in battle over app's fate
- European, US markets wobble awaiting Santa rally
- NASA solar probe to make its closest ever pass of Sun
- Volkswagen boss hails cost-cutting deal but shares fall
- Sweden says China blocked prosecutors' probe of ship linked to cut cables
- UK economy stagnant in third quarter in fresh setback
- Global stock markets edge higher as US inflation eases rate fears
- US probes China chip industry on 'anticompetitive' concerns
- Mobile cinema brings Tunisians big screen experience
- Honda and Nissan to launch merger talks
- Asian markets track Wall St rally as US inflation eases rate fears
- Honda and Nissan expected to begin merger talks
- Asian markets track Wall St rally as US inflation eases rate worries
- Trump vows to 'stop transgender lunacy' as a top priority
- Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence
- Sweet smell of success for niche perfumes
- 'Finally, we made it!': Ho Chi Minh City celebrates first metro
- Tunisia women herb harvesters struggle with drought and heat
- Trump threatens to take back control of Panama Canal
- Secretive game developer codes hit 'Balatro' in Canadian prairie province
- Stellantis backtracks on plan to lay off 1,100 at US Jeep plant
- Banned Russian skater Valieva stars at Moscow ice gala
- Biden signs funding bill to avert government shutdown
- Sorrow and fury in German town after Christmas market attack
- France's most powerful nuclear reactor finally comes on stream
- Sierra Leone student tackles toxic air pollution
- Amazon says US strike caused 'no disruptions'
- Qualcomm scores key win in licensing dispute with Arm
- Scientists observe 'negative time' in quantum experiments
- US approves first drug treatment for sleep apnea
- Amazon expects no disruptions as US strike goes into 2nd day
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
S.F.Lacroix--CPN